IBEX 35
11.105,50 +55,40 (+0,50%) Euro Stoxx 50
5.085,08 +30,67 (+0,61%) Dólar/Euro
1,0772 -0,0012 (-0,11%) Petróleo Brent
82,73 -1,15 (-1,37%) Oro
2.366,90 +26,60 (+1,14%) Bitcoin EUR
56.750,06 +361,12 (+0,64%)
Reviva Pharmaceuticals Holdings, Inc. (RVPH)
Después del cierre:
Reviva Pharmaceuticals Holdings, Inc.
10080 N. Wolfe Road
Suite SW3-200
Cupertino, CA 95014
United States
408-501-8881
https://www.revivapharma.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 15
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Laxminarayan Bhat Ph.D. | Founder, CEO, President & Director | 450k | N/A | 1965 |
| Mr. Narayan Prabhu | Chief Financial Officer | 325k | N/A | 1972 |
Descripción
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.
Gobierno corporativo
El ISS Governance QualityScore de Reviva Pharmaceuticals Holdings, Inc., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.
